Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.
The diversified health-care firm remains remarkably profitable in tough industries.
Morningstar's Heather Brilliant says investors could see a lot of market volatility this upcoming earnings season, but that could make for tremendous buying opportunities of quality names.
Morningstar StockInvestor editor Matt Coffina discusses recent additions to the Wide Moat Focus Index.
Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.
Morningstar StockInvestor editor Matt Coffina highlights three of the highest-quality companies we cover.
Morningstar StockInvestor editor Matt Coffina explains why he recently purchased Novo Nordisk for StockInvestor's real-money Hare portfolio.
Some users find value in dividend-paying blue chips, while others are compiling watchlists and waiting for a pullback.
A look at how our 2012 Fund Managers of the Year stack up against their benchmarks.
These skippers shone amid a challenging market environment.